British Journal of Haematology

Papers
(The H4-Index of British Journal of Haematology is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
COVID‐19‐associated immune thrombocytopenia129
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature118
COVID‐19 and ABO blood group: another viewpoint100
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma99
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation92
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma92
The association between severe COVID‐19 and low platelet count: evidence from 31 observational studies involving 7613 participants91
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry89
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐ca85
Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic82
Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID‐19?82
Updates on targeted therapies for acute myeloid leukaemia81
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience81
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients78
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients75
Disseminated intravascular coagulation: epidemiology, biomarkers, and management73
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies72
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations70
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination69
Impact of COVID‐19 on red blood cell rheology69
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy67
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma65
Dynamic relationship between D‐dimer and COVID‐19 severity65
Machine learning and artificial intelligence in haematology64
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity64
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data62
Guidelines on the use of irradiated blood components62
COVID‐19 infection and sickle cell disease: a UK centre experience61
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐1958
Prevalence of venous thromboembolism in critically ill patients with COVID‐1956
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy55
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies55
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?54
First COVID‐19 maternal mortality in the UK associated with thrombotic complications54
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)52
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma50
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye49
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies49
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients48
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients48
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents48
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐1947
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant46
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold46
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience46
Efficacy of therapeutic plasma exchange in severe COVID‐19 patients46
0.04761815071106